Announcements

The latest Impact Factors have been released and are updated in our site!

Not a Current Subscriber?

Subscribe Now

5642 Journals

4484 Congresses

10100+ Unique Records

Therapeutic Advances in Vaccines and Immunotherapy

Title Abbreviation

Ther Adv Vaccines Immunother

ISSN

2515-1355

Electronic ISSN

2515-1363

Therapeutic Area

Health Economics/Outcomes Research, Immunology, Molecular Medicine, Pharmacoeconomics, Pharmacology, Vaccines/Vaccinology

Readership

Clinicians, Health Scientists, Immunologists, Infectious Disease Specialists, Internists, Interventionalists, Molecular Biologists, Oncologists, Pharmaco-Epidemiologists, Pharmacologists, Physicians, Physicians - Medicine

Scope

Therapeutic Advances in Vaccines and Immunotherapy delivers the highest quality peer-reviewed open access articles, reviews, and scholarly comment relating to advances in the fields of vaccinology and immunotherapy. It is now recognised that the immune response can be manipulated in a plethora of different ways that can ultimately deliver therapeutic output for infectious disease, chronic disease and cancer in patients. As such, there has been a recent explosion of research activity investigating different immunotherapeutic strategies, which has been driven in part by the successful impact of checkpoint inhibitors in hitherto treatment-resistant cancers such as melanomas. The journal covers all research relevant to the prospects of recovering a natural, or enhancing an induced, immune response, reporting on advances in vaccination (both prophylactic and therapeutic) as well as an ever-growing repertoire of other immunotherapeutic interventions. The journal is dedicated to publishing clinical research. We do not publish preclinical research, including basic laboratory research and animal studies. Review articles include expert opinion/perspective reviews (including single-drug and drug class reviews), narrative reviews and therapeutic area reviews. Systematic reviews, meta-analyses, post-marketing and health economic and pharmacoeconomic reviews are also welcomed. The appropriate EQUATOR Network reporting guidelines should be followed (e.g. CONSORT for randomized, controlled trials and PRISMA for systematic reviews/meta-analyses). Therapeutic Advances in Medical Oncology conforms to the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrolment as a condition of consideration for publication. The trial registry name and URL, and registration number must be included at the end of the abstract. The journal adheres to a blind review process in which the reviewer's name is routinely withheld from the author unless the reviewer requests a preference for their identity to be revealed. Manuscripts are reviewed by at least two referees; and Online First publication is usually within 3 weeks of acceptance.

Sponsoring Association(s)

No associations affiliated with this journal

Publisher Name

SAGE Publications - UK

To see more details about Therapeutic Advances in Vaccines and Immunotherapy, Subscribe Now!

Submission to Acceptance Acceptance to Online Publication Rejection Rate Frequency Journal Contact Author Submission Guidelines

Testimonials

"PubsHub [Journals & Congresses] is an indispensable tool when trying to find the perfect home for a manuscript. It is an unbeatable aid when it comes to wise and efficient journal selection."
	– Kait G Editorial-Project Editor
"It’s useful for establishing publication timelines, communicating them to management and setting expectations accordingly"
	– Michael K. Medical Communications Leader
"…a gold mine of information for clinicians and scientists who are trying to determine where to publish their research."
	- Weill Cornell Medical Library

Journals ● Congresses ● Associations

Privacy Policy ● Terms of Service ● Glossary ● OSS ● Contact Us